Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R FlahertyAthol U WellsVincent CottinAnand DevarajSimon L F WalshYoshikazu InoueLuca RicheldiMartin KolbKay TetzlaffSusanne StowasserCarl CoeckEmmanuelle Clerisme-BeatyBernd RosenstockManuel QuaresmaThomas HaeufelRainer-Georg GoeldnerRozsa Schlenker-HercegKevin K Brownnull nullPublished in: The New England journal of medicine (2019)
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. (Funded by Boehringer Ingelheim; INBUILD ClinicalTrials.gov number, NCT02999178.).